Transgene SA TRGNF

TRGNF Company Overview

Transgene SA is a France-based biotechnology company focused on the research, development, and commercialization of immunotherapies for cancer and infectious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on viral vector technologies, oncolytic viruses, therapeutic vaccines, and individualized immunotherapy platforms. Its primary revenue sources have historically included research collaborations, licensing agreements, milestone payments, and public funding support, rather than large-scale commercial product sales. Transgene’s development programs are primarily directed toward oncology indications, including solid tumors and virus-associated cancers.

The company was founded in 1979 and is headquartered in Strasbourg, France. Transgene became affiliated with the Institut Mérieux ecosystem, which remains a significant shareholder through related investment entities. Over time, the company evolved from a broader biotechnology research organization into a specialized immunotherapy developer focused on engineered viral platforms. Its strategic positioning is based on proprietary viral engineering capabilities, translational research infrastructure, and collaborations with academic institutions and pharmaceutical partners focused on precision immuno-oncology.